Search results
Search for "mitochondria" in Full Text gives 33 result(s) in Beilstein Journal of Organic Chemistry.
Green and sustainable approaches for the Friedel–Crafts reaction between aldehydes and indoles
- Periklis X. Kolagkis,
- Eirini M. Galathri and
- Christoforos G. Kokotos
Beilstein J. Org. Chem. 2024, 20, 379–426, doi:10.3762/bjoc.20.36
- general extends to other types of cancers as well, such as prostate cancer by being an androgen receptor (AR) agonist in LNCaP prostate cancer cells [6]. DIM controls cell growth rates in AR-negative cells, while also targeting the mitochondria inducing apoptosis, which alleviates some of the symptoms of
Graphical Abstract
Scheme 1: Examples of BIMs used for their medicinal properties.
Scheme 2: Mechanisms for the synthesis of BIMs using protic or Lewis acids as catalysts.
Scheme 3: Synthesis of bis(indolyl)methanes using DBDMH.
Scheme 4: Competition experiments and synthesis of bis(indolyl)methanes using DBDMH.
Scheme 5: Proposed mechanism for formation of BIM of using DBDMH.
Scheme 6: Synthesis of bis(indolyl)methanes using I2.
Scheme 7: General reaction mechanism upon halogen bonding.
Scheme 8: Synthesis of bis(indolyl)methanes using I2, introduced by Ji.
Scheme 9: Synthesis of bis(indolyl)methanes using Br2 in CH3CN.
Scheme 10: Βidentate halogen-bond donors.
Scheme 11: Synthesis of bis(indolyl)methanes using bidentate halogen-bond donor 26.
Scheme 12: Proposed reaction mechanism.
Scheme 13: Synthesis of bis(indolyl)methanes using iodoalkyne as catalyst.
Scheme 14: Proposed reaction mechanism.
Scheme 15: Optimized reaction conditions used by Ramshini.
Scheme 16: Activation of the carbonyl group by HPA/TPI-Fe3O4.
Scheme 17: Synthesis of BIMs in the presence of nanoAg-Pt/SiO2-doped silicate.
Scheme 18: Mechanism of action proposed by Khalafi-Nezhad et al.
Scheme 19: Activation of the carbonyl group by the Cu–isatin Schiff base complex.
Scheme 20: Optimum reaction conditions published by Jain.
Scheme 21: Organocatalytic protocol utilizing nanoparticles introduced by Bankar.
Scheme 22: Activation of the carbonyl group by the AlCl3·6H2O-SDS-SiO2 complex.
Scheme 23: Optimal reaction conditions for the aforementioned nano-Fe3O4 based catalysts.
Scheme 24: Nanocatalytic protocol proposed by Kaur et al.
Scheme 25: Microwave approach introduced by Yuan.
Scheme 26: Microwave approach introduced by Zahran et al.
Scheme 27: Microwave irradiation protocol introduced by Bindu.
Scheme 28: Silica-supported microwave irradiation protocol.
Scheme 29: Proposed mechanism for formation of BIM by Nongkhlaw.
Scheme 30: Microwave-assisted synthesis of BIMs catalyzed by succinic acid.
Scheme 31: Proposed mechanism of action of MMO-4.
Scheme 32: Catalytic approach introduced by Muhammadpoor-Baltork et al.
Scheme 33: Reaction conditions used by Xiao-Ming.
Scheme 34: Ultrasonic irradiation-based protocol published by Saeednia.
Scheme 35: Pyruvic acid-mediated synthesis of BIMs proposed by Thopate.
Scheme 36: Synthesis of BIMs using [bmim]BF4 or [bmim]PF6 ionic liquids.
Scheme 37: Synthesis of BIMs utilizing In(OTf)3 in octylmethylimidazolium hexafluorophosphate as ionic liquid.
Scheme 38: FeCl3·6H2O-catalyzed synthesis of BIMs with use of ionic liquid.
Scheme 39: Synthesis of BIMs utilizing the [hmim]HSO4/EtOH catalytic system.
Scheme 40: Synthesis of BIMs utilizing acidic ionic liquid immobilized on silica gel (ILIS-SO2Cl).
Scheme 41: The [bmim][MeSO4]-catalyzed reaction of indole with various aldehydes.
Scheme 42: The role of [bmim][MeSO4] in catalyzing the reaction of indole with aldehydes.
Scheme 43: Synthesis of BIMs utilizing FeCl3-based ionic liquid ([BTBAC]Cl-FeCl3) as catalyst.
Scheme 44: Synthesis of BIMs using [Msim]Cl at room temperature.
Scheme 45: [Et3NH][H2PO4]-catalyzed synthesis of bis(indolyl)methanes.
Scheme 46: PILs-catalyzed synthesis of bis(indolyl)methanes.
Scheme 47: FSILs-mediated synthesis of bis(indolyl)methanes.
Scheme 48: Possible “release and catch” catalytic process.
Scheme 49: Synthesis of bis(indolyl)methanes by [DABCO-H][HSO4].
Scheme 50: Synthesis of bis(indolyl)methanes by [(THA)(SO4)].
Scheme 51: Synthesis of BBSI-Cl and BBSI-HSO4.
Scheme 52: Synthesis of BIMs in the presence of BBSI-Cl and BBSI-HSO4.
Scheme 53: Chemoselectivity of the present method.
Scheme 54: Synthesis of BIMs catalyzed by chitosan-supported ionic liquid.
Scheme 55: Proposed mechanism of action of CSIL.
Scheme 56: Optimization of the reaction in DESs.
Scheme 57: Synthesis of BIMs using ChCl/SnCl2 as DES.
Scheme 58: Synthesis of BIMs derivatives in presence of DES.
Scheme 59: BIMs synthesis in choline chloride/urea (CC/U).
Scheme 60: Flow chemistry-based synthesis of BIMs by Ley.
Scheme 61: Flow chemistry-based synthesis of BIMs proposed by Nam et al.
Scheme 62: Amino-catalyzed reaction of indole with propionaldehyde.
Scheme 63: Aminocatalytic synthesis of BIMs.
Scheme 64: Proposed mechanism for the aminocatalytic synthesis of BIMs.
Scheme 65: Enzymatic reaction of indole with aldehydes.
Scheme 66: Proposed mechanism for the synthesis of BIMs catalyzed by TLIM.
Scheme 67: Proposed reaction mechanism by Badsara.
Scheme 68: Mechanism proposed by D’Auria.
Scheme 69: Photoinduced thiourea catalysis.
Scheme 70: Proposed mechanism of photoacid activation.
Scheme 71: Proposed mechanism of action for CF3SO2Na.
Scheme 72: Proposed mechanism for the synthesis of BIMs by Mandawad.
Scheme 73: Proposed mechanism for the (a) acid generation and (b) synthesis of BIMs.
Scheme 74: a) Reaction conditions employed by Khaksar and b) activation of the carbonyl group by HFIP.
Scheme 75: Activation of the carbonyl group by the PPy@CH2Br through the formation of a halogen bond.
Scheme 76: Reaction conditions utilized by Mhaldar et al.
Scheme 77: a) Reaction conditions employed by López and b) activation of the carbonyl group by thiourea.
Scheme 78: Infrared irradiation approach introduced by Luna-Mora and his research group.
Scheme 79: Synthesis of BIMs with the use of the Fe–Zn BMOF.
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
- the endoplasmic reticulum (ER). Then, ELs are spread off in the cell, to the plasma membranes but also in other biomembranes (membrane of mitochondria, ER, nucleus). The occurrence of ELs in tissues was first assessed by Snyder and Woods who reported that neutral ELs and phosphoglycero ELs were
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Post-functionalization of drug-loaded nanoparticles prepared by polymerization-induced self-assembly (PISA) with mitochondria targeting ligands
- Janina-Miriam Noy,
- Fan Chen and
- Martina Stenzel
Beilstein J. Org. Chem. 2021, 17, 2302–2314, doi:10.3762/bjoc.17.148
- methacrylate) (pPEGMA) and the anticancer drug PENAO (4-(N-(S-penicillaminylacetyl)amino)phenylarsenonous acid) or zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) and PENAO were reported. Both PISA particles were reacted with triphenylphosphonium (TPP) as mitochondria targeting units in order to
- cells. When TPP was conjugated to the pMPC PISA particles more cellular uptake as well as better spheroid penetration were observed, while TPP on PEG-based PISA had only little effect. It was hypothesized that TPP on the micelle surface may not be accessible enough to allow mitochondria targeting, but
- more structural investigations are required to elucidate this. Keywords: micelle; mitochondria; phosphorylcholine; PISA; polymerization-induced self-assembly; Introduction Targeting mitochondria is a promising strategy for the development of new anticancer drugs [1]. Among them, organoarsenical drugs
Graphical Abstract
Figure 1: (I) DLS of PPM-NP4, MPM-NP2, PPM-NP4-TPP and MPM-NP2-TPP and (II) TEM of PPM-NP4-TPP and MPM-NP2-TPP...
Figure 2: Representative 31P NMR (top) and 1H NMR (bottom) spectrum of PP3-TPP conjugation product in D2O.
Scheme 1: Synthesis of TPP-based PISA particles based on zwitterionic 2-methacryloyloxyethyl phosphorylcholin...
Figure 3: Penetration of PPM-NP4-TPP and MPM-NP2-TPP micelles and fluorescence intensity profile on (A I, II)...
Figure 4: Growth effects of PPM-NP4-TPP and MPM-NP2-TPP on SW982 spheroids after 3 and 6 days of incubation (c...
Figure 5: Cell viability of SW982 spheroids after 6 days treatment with PPM-NP4, PPM-NP-TPP, MPM-NP2 and MPM-...
Figure 6: Cell localization of PPM-NP4-TPP (I) and MPM-NP2-TPP (II) into (A) mitochondria and (B) lysosomes u...
Figure 7: Cytotoxicity study of PPM-NP4-TPP and MPM-NP2-TPP on SW982 cells in relation to the concentration o...
Chemical approaches to discover the full potential of peptide nucleic acids in biomedical applications
- Nikita Brodyagin,
- Martins Katkevics,
- Venubabu Kotikam,
- Christopher A. Ryan and
- Eriks Rozners
Beilstein J. Org. Chem. 2021, 17, 1641–1688, doi:10.3762/bjoc.17.116
Graphical Abstract
Figure 1: Structure of DNA and PNA.
Figure 2: PNA binding modes: (A) PNA–dsDNA 1:1 triplex; (B) PNA–DNA–PNA strand-invasion triplex; (C) the Hoog...
Figure 3: Structure of P-form PNA–DNA–PNA triplex from reference [41]. (A) view in the major groove and (B) view ...
Figure 4: Structures of backbone-modified PNA.
Figure 5: Structures of PNA having α- and γ-substituted backbones.
Figure 6: Structures of modified nucleobases in PNA to improve Hoogsteen hydrogen bonding to guanine and aden...
Figure 7: Proposed hydrogen bonding schemes for modified PNA nucleobases designed to recognize pyrimidines or...
Figure 8: Modified nucleobases to modulate Watson–Crick base pairing and chemically reactive crosslinking PNA...
Figure 9: Examples of triplets formed by Janus-wedge PNA nucleobases (blue). R1 denotes DNA, RNA, or PNA back...
Figure 10: Examples of fluorescent PNA nucleobases. R1 denotes DNA, RNA, or PNA backbones.
Figure 11: Endosomal entrapment and escape pathways of PNA and PNA conjugates.
Figure 12: (A) representative cell-penetrating peptides (CPPs), (B) conjugation designs and linker chemistries....
Figure 13: Proposed delivery mode by pHLIP-PNA conjugates (A) the transmembrane section of pHLIP interacting w...
Figure 14: Structures of modified penetratin CPP conjugates with PNA linked through either disulfide (for stud...
Figure 15: Chemical structure of C9–PNA, a stable amphipathic (cyclic-peptide)–PNA conjugate.
Figure 16: Structures of PNA conjugates with a lipophilic triphenylphosphonium cation (TPP–PNA) through (A) th...
Figure 17: Structures of (A) chloesteryl–PNA, (B) cholate–PNA and (C) cholate–PNA(cholate)3.
Figure 18: Structures of PNA–GalNAc conjugates (A) (GalNAc)2K, (B) triantennary (GalNAc)3, and (C) trivalent (...
Figure 19: Vitamin B12–PNA conjugates with different linkages.
Figure 20: Structures of (A) neomycin B, (B) PNA–neamine conjugate, and (C) PNA–neosamine conjugate.
Figure 21: PNA clamp (red) binding to target DNA containing a mixture of sequences (A) PNA binds with higher a...
Figure 22: Rolling circle amplification using PNA openers (red) to invade a dsDNA target forming a P-loop. A p...
Figure 23: Molecular beacons containing generic fluorophores (Fl) and quenchers (Q) recognizing a complementar...
Figure 24: (A) Light-up fluorophores such as thiazole orange display fluorescence enhancement upon binding to ...
Figure 25: Templated fluorogenic detection of oligonucleotides using two PNAs. (A) Templated FRET depends on h...
Figure 26: Lateral flow devices use a streptavidin labeled strip on nitrocellulose paper to anchor a capture P...
Enzyme-instructed morphological transition of the supramolecular assemblies of branched peptides
- Dongsik Yang,
- Hongjian He and
- Bing Xu
Beilstein J. Org. Chem. 2020, 16, 2709–2718, doi:10.3762/bjoc.16.221
- serendipitously found that an enzyme-responsive branched peptide was able to deliver small molecules or proteins to mitochondria efficiently in a cell-specific manner [33]. The branched peptide, which bears FLAG-tag as the branch [32], forms micelles. Certain proteases on the mitochondria of certain cells cleave
- the branch of the peptide, and such enzymatic proteolysis turns the micelles into nanofibers. This morphological transition (i.e., micelle to nanofiber) releases the cargos into the mitochondria of the cells [33]. These results imply that enzyme-responsive branched peptides can act as responsive
Graphical Abstract
Figure 1: A) The molecular structures of the branched peptides Nap-ffk(NH2-DEDDDLLIG)y (1) and Nap-ffk(AcNH-D...
Scheme 1: Synthetic route to the branched peptides. (i) HBTU, DIPEA, DMF, 12 h, rt, (ii) TFA, 2 h, rt, and (i...
Figure 2: A) LC–MS spectrum of the proteolytic products after 1 (5 mM) was incubated with proteinase K (5 U/m...
Figure 3: Optical images of solutions of 1 and 2 (5 mM), respectively, with or without proteinase K (5 U/mL) ...
Figure 4: TEM images of the branched peptides before and after the addition of proteinase K into the solution...
Figure 5: Cell viability of HeLa and Saos-2 cells treated with 1 (A) and 2 (B).
Figure 6: Confocal images of HeLa cells treated with a mixture of RPE (8 μg/mL) and A) 1 (400 μM) or B) 2 (40...
Automated high-content imaging for cellular uptake, from the Schmuck cation to the latest cyclic oligochalcogenides
- Rémi Martinent,
- Javier López-Andarias,
- Dimitri Moreau,
- Yangyang Cheng,
- Naomi Sakai and
- Stefan Matile
Beilstein J. Org. Chem. 2020, 16, 2007–2016, doi:10.3762/bjoc.16.167
- protein were used to segment whole cells and mitochondria, respectively (blue and yellow areas, Figure 7a). The structural characteristics of the cells were extracted from both masks. Possible damaged cells with early signs of apoptosis or abnormal mitochondrial networks were excluded (Figure 7a, right
- , masking exclusively the mitochondria region, gave a small but significant increase to r2 = 0.983 (Figure 8b). Although optimized toward perfection with stable HGM cells, this increase demonstrated that the HC CAPA adds a precision that is overlooked with flow cytometry. The off-target staining of 26 in
- regions outside mitochondria accounted for this source of error in the CAPA, which is corrected in the HC CAPA (Figure 7b, arrows). The optimized HC CAPA system was then explored with the complex 25, recording the cytosolic delivery and the cytotoxicity quantitatively in one HT experiment. A nearly
Graphical Abstract
Figure 1: Schematic representation of binding models between organic cations (simple ammonium, guanidinium, S...
Figure 2: From Schmuck cations to cell-penetrating dipeptides, with schematic representation of the binding m...
Figure 3: Peptide tweezers and cyclic peptides with Schmuck cations for gene transfection.
Figure 4: Evolution from CPPs to CPDs and COCs.
Figure 5: Structure of a) the trifunctional transporter 23 and c) the HaloTag reporter 26. b) Schematic mecha...
Figure 6: CAPA assay for the complex 25, composed of three transporters 23 bound to one streptavidin 24 (with...
Figure 7: Examples from the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 8: Evaluation of the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 9: a) Automated HC imaging of the cellular uptake of 25, covering the concentration dependence for the...
Figure 10: Examples of automated HC imaging of transiently transfected HeLa cells with HaloTag–GFP on Golgi, l...
Figure 11: Evaluation of the automated HC imaging of the transiently transfected HeLa cells with HaloTag–GFP o...
Plasma membrane imaging with a fluorescent benzothiadiazole derivative
- Pedro H. P. R. Carvalho,
- Jose R. Correa,
- Karen L. R. Paiva,
- Daniel F. S. Machado,
- Jackson D. Scholten and
- Brenno A. D. Neto
Beilstein J. Org. Chem. 2019, 15, 2644–2654, doi:10.3762/bjoc.15.257
- for all tested models. Keywords: benzothiadiazole; bioprobe; cell imaging; fluorescence; mitochondria; molecular architecture; plasma membrane; Introduction The selective staining of plasma membranes is of paramount importance to study cellular processes and events associated with this dynamic
Graphical Abstract
Figure 1: The 2,1,3-benzothiadiazole (BTD) core and its derivatives that are successfully applied in bioimagi...
Scheme 1: Synthesis of the plasma membrane BTD probe (BTD-4APTEG) and its structural features.
Figure 2: (Left) UV–vis, (center) fluorescence emission and (right) solvatochromic effect (Stokes shift in wa...
Figure 3: Mean absolute error (MAE) comparing both the experimental and the estimated TD-DFT λmax positions i...
Figure 4: (A) CAM-B3LYP/6-311+G(d) optimized geometry of BTD-4APTEG (implicit DMSO). (B) TD-DFT UV–vis spectr...
Figure 5: Cellular viability determined by MTT analysis after 24 h treatment with the developed dye BTD-4APTE...
Figure 6: MCF-7 cells incubated with BTD-4APTEG (1 μM) in live (A) and (B) and fixed cells (C) and (D). (A) a...
Figure 7: Co-staining experiments using the commercially available CellMask (red emission) and BTD-4APTEG (gr...
α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHA
- Shital K. Chattopadhyay,
- Subhankar Ghosh,
- Sarita Sarkar and
- Kakali Bhadra
Beilstein J. Org. Chem. 2019, 15, 2524–2533, doi:10.3762/bjoc.15.245
- potential dependent accumulation in mitochondria, indicated by a fluorescence emission shift from red to green. The exposure of 11b to the cells caused remarkable loss of mitochondrial membrane potential, hence the fluorescence gradually shifted from red to green as the membrane potential (Ψm) decreased
Graphical Abstract
Figure 1: Some hydroxamic acid-based anti-tumor drugs.
Scheme 1: Synthesis of SAHA and DDSAHA.
Figure 2: Cell viability from MTT assay for SAHA, 11b, 11f and 11g on HeLa after 24 h treatment.
Figure 3: Percent of cell death by LDH assay at a GI50 dose of SAHA, 11b, 11f and 11g after 24 h incubation a...
Figure 4: ROS generation by DCFDA.
Figure 5: The quantitative results of bivariate FITC-Annexin V/PI FCM of HeLa cells after treatment with 11b ...
Figure 6: Fluorescence microscopic images of 11b at different concentrations (8.9, and 14.2 µM, respectively)...
Figure 7: DNA Ladder formation in a gel electrophoresis study of 11b at different concentrations (at 8.9, and...
Synthesis of a dihalogenated pyridinyl silicon rhodamine for mitochondrial imaging by a halogen dance rearrangement
- Jessica Matthias,
- Thines Kanagasundaram,
- Klaus Kopka and
- Carsten S. Kramer
Beilstein J. Org. Chem. 2019, 15, 2333–2343, doi:10.3762/bjoc.15.226
- the use in multimodal (PET/OI) medical imaging of mitochondria in cancerous cells. Results: A dihalogenated fluorinatable pyridinyl rhodamine could be successfully synthesized with the high yield of 85% by application of a halogen dance (HD) rearrangement. The near-infrared dye shows a quantum yield
- of 0.34, comparable to other organelle targeting SiR derivatives and absorbs at 665 nm (εmax = 34 000 M−1cm−1) and emits at 681 nm (τ = 1.9 ns). Using colocalization experiments with MitoTracker® Green FM, we could prove the intrinsic targeting ability to mitochondria in two human cell lines (Pearson
- optical properties for medical and bioimaging. As a compound with intrinsic mitochondria targeting ability, the radiolabelled analogue can be applied in multimodal (PET/OI) imaging of mitochondria for diagnostic and therapeutic use in, e.g., cancer patients. Keywords: halogen-dance reaction
Graphical Abstract
Scheme 1: Comparison of optical properties of different silicon rhodamines.
Scheme 2: Retrosynthetic analysis of the proposed small molecule bimodal probe [18F]16 for both optical and P...
Scheme 3: Optimization of the HD rearrangement of 19 and subsequent reaction with xanthone 17 to the silicon ...
Figure 1: (a) Absorption and fluorescence emission spectra of dye 15 measured in PBS buffer pH 7.4. (b, c) Co...
Figure 2: STED and confocal images of the mitochondrial network in living HeLa cells stained with 1 µM SiR dy...
Figure 3: Exemplary holographic image sequence of two cell divisions of U2OS cells treated with 1 µM of dye 15...
Archangelolide: A sesquiterpene lactone with immunobiological potential from Laserpitium archangelica
- Silvie Rimpelová,
- Michal Jurášek,
- Lucie Peterková,
- Jiří Bejček,
- Vojtěch Spiwok,
- Miloš Majdl,
- Michal Jirásko,
- Miloš Buděšínský,
- Juraj Harmatha,
- Eva Kmoníčková,
- Pavel Drašar and
- Tomáš Ruml
Beilstein J. Org. Chem. 2019, 15, 1933–1944, doi:10.3762/bjoc.15.189
- archangelica Wulfen using supercritical CO2 extraction. We show that dansyl-archangelolide localizes in the endoplasmic reticulum of living cells similarly to trilobolide; localization in mitochondria was also detected. This led us to a more detailed study of the anticancer potential of archangelolide
- partial co-localization also in mitochondria, in which SERCA is not present. Localization of a control (dansyl fluorophore) was not organelle-specific and the fluorescence intensity was very weak even at 2 µM concentration (Supporting Information File 1, Figure S18). Impact of compound 1 on cell viability
- mitochondria of both cancer and normal cells. This led us to examine the binding of compound 1 to SERCA, the target of compound 2 and thapsigargin, by a docking study. Indeed, the results strongly argue that compound 1 is biologically very distinct from the other two SLs, since it does not bind and probably
Graphical Abstract
Figure 1: The structure of the sesquiterpene lactones archangelolide (1) and trilobolide (2).
Scheme 1: Reagents and conditions: a) MeOH, TEA, 48 h, yield 32%; b) (i) 5-azidopentanoic acid, DCC, DCM, 90 ...
Figure 2: Intracellular localization of archangelolide-dansyl (5) in human cells from osteosarcoma (U-2 OS). ...
Figure 3: Co-localization of dansylarchangelolide 5 with a marker of endoplasmic reticulum (top row) and with...
Figure 4: Cartoon representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A, C) archang...
Figure 5: Molecular surface representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A) ...
Figure 6: Structural formulae of (i) thapsigargin, (ii) trilobolide (2), and (iii) archangelolide (1). Red pa...
Figure 7: Viability of rat peritoneal cells treated with archangelolide (1), dansylarchangelolide 5 and dansy...
Figure 8: NO production in primary rat macrophages. The cells were treated with archangelolide (1) and dansyl...
Figure 9: Evaluation of cytokine TNF-α secretion in rat peritoneal cells. Stimulation of primary cells was in...
Figure 10: Structure of laserolide.
Identification of optimal fluorescent probes for G-quadruplex nucleic acids through systematic exploration of mono- and distyryl dye libraries
- Xiao Xie,
- Michela Zuffo,
- Marie-Paule Teulade-Fichou and
- Anton Granzhan
Beilstein J. Org. Chem. 2019, 15, 1872–1889, doi:10.3762/bjoc.15.183
- propensity of cationic dyes to accumulate in mitochondria. At the same time, our work establishes an approach to optimize the structure of renowned scaffolds and achieve maximal performances in G4 sensing. Some di- and mono-styryl dyes previously reported as fluorescent “light-up” probes for G4-DNA and RNA
Graphical Abstract
Figure 1: Some di- and mono-styryl dyes previously reported as fluorescent “light-up” probes for G4-DNA and R...
Figure 2: Design of a library of di- and mono-styryl dyes. Counter-ions are omitted for the sake of clarity.
Scheme 1: A, B) General synthesis of A) distyryl and B) mono-styryl dyes via Knoevenagel condensation route. ...
Scheme 2: Synthesis of I3–5 and I15.
Figure 3: Representative absorption spectra of distyryl dyes: A) 1d, B) 1ð, C) 1f, D) 1u, E) 10a and F) 12a i...
Figure 4: Representative absorption spectra of the distyryl dyes (c = 10 µM in MeOH) demonstrating the influe...
Figure 5: Heat map of the relative emission intensity enhancement (I/I0) of styryl dyes and thioflavin T (ThT...
Figure 6: Analysis of the light-up response matrix of the dyes. The average light-up factor of each dye with ...
Figure 7: PC1 vs PC2 plot obtained from the principal component analysis of the light-up data matrix for all ...
Figure 8: Dual-dye conformational analysis of an extended panel of 33 DNA oligonucleotides. This is performed...
Figure 9: Selected probes featuring high fluorimetric response towards G4 structures.
Figure 10: Photographs of solutions of A) distyryl dyes 1p and 1u; B) mono-styryl dyes 17a and 18a, in the abs...
Protein–protein interactions in bacteria: a promising and challenging avenue towards the discovery of new antibiotics
- Laura Carro
Beilstein J. Org. Chem. 2018, 14, 2881–2896, doi:10.3762/bjoc.14.267
- ]. LCL-161 (3, Figure 2), an inhibitor of the interaction between Smac (second mitochondria-derived activator of caspases) and IAP (inhibitor of apoptosis proteins) developed by Novartis, has recently entered phase II for the treatment of leukaemia [29]. Another example is the inhibitor of the BET
Graphical Abstract
Figure 1: Illustration of a PPI modulator (stabilizer or inhibitor) vs a traditional drug target.
Figure 2: Examples of protein–protein interaction modulators in clinical trials or in clinical use.
Figure 3: Small-molecule inhibitors of PPIs in the β-sliding clamp.
Figure 4: Crystal structure of the RU7 (9)-sliding clamp complex (PDB code 3D1G; adapted from Georgescu et al...
Figure 5: Peptidic inhibitors of PPIs in the sliding clamp.
Figure 6: SSB protein–protein interaction inhibitors identified by HTS.
Figure 7: SSB protein–protein interaction inhibitors identified by FBDD.
Figure 8: Examples of molecules that disrupt the ZipA/FtsZ interaction.
Figure 9: Inhibitors of the NusB/NusE interaction.
Targeting the Pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers
- Christian Schütz and
- Martin Empting
Beilstein J. Org. Chem. 2018, 14, 2627–2645, doi:10.3762/bjoc.14.241
- [38]. HQNO acts through inhibition of complex III in the respiratory chain of bacteria and mitochondria of eukaryotes and, hence, it can be considered a general cytotoxic agent. DHQ, a shunt product of the PQS biosynthetic pathway, is important for P. aeruginosa virulence in a Caenorhabditis elegans
Graphical Abstract
Figure 1: The four quorum sensing systems in P. aeruginosa las, iqs, rhl, and pqs. Abbreviations: OdDHL, N-(3...
Figure 2: Schematic overview of the PQS biosynthesis and involvement of related metabolites and PqsE in virul...
Figure 3: Anthranilic acid (1) and derivatives thereof (2–4).
Figure 4: Crystal structure of 6-FABA-AMP in complex with PqsA.
Figure 5: Structures of substrate mimetic PqsA inhibitors.
Figure 6: Structures and characteristics of prominent classes of PqsD inhibitors.
Figure 7: Comparison of docking poses of three prototypic PqsD inhibitors: benzamidobenzoic acid derivative 12...
Figure 8: Structures and characteristics of hits against PqsD identified through different methods.
Figure 9: HHQ and PQS analogues as PqsD inhibitors and chemical probe used for screening.
Figure 10: Structure of PqsD-targeting biofilm inhibitor derived from linezolid.
Figure 11: Fragment-based PqsE-inhibitors 24–26.
Figure 12: PqsE co-crystal structures. (A) native product 2-ABA; (B–D) hit fragments 24–26.
Figure 13: Structurally diverse PqsBC-inhibitors 27–30.
Figure 14: Native PqsR ligand HHQ (31) which is converted into PQS (32) by PqsH and synthetic inhibitors 33 an...
Figure 15: Quinazolinone inhibitor 36 (QZN).
Figure 16: Crystal structure of QZN (36) in complex with PqsRCBD.
Figure 17: Structures of best fitting compounds 37–40 obtained from docking studies.
Figure 18: Initial hit 21 and optimized compound 42 (M64).
Figure 19: Co-crystal structure of M64 (42) with PqsRLBD.
Figure 20: M64 (42) as the starting point for further optimization leading to 43, which was further modified a...
Figure 21: Hit fragments from the benzamide (47–48) and oxadiazole class (49–51).
Figure 22: Structures of dual inhibitors 52–55.
Figure 23: Sulfonyl pyrimidines 56–58 acting as dual PqsD/PqsR inhibitors.
Hydroarylations by cobalt-catalyzed C–H activation
- Rajagopal Santhoshkumar and
- Chien-Hong Cheng
Beilstein J. Org. Chem. 2018, 14, 2266–2288, doi:10.3762/bjoc.14.202
- limited to terminal alkynes. Additionally, they applied this methodology to design a mitochondria-targeted imaging dye from electron-withdrawing formyl-substituted indoles and alkynes. Later, Maji’s group reported an N-tert-butyl amide-directed mono- and di-alkenylation reactions using a cobalt catalyst
Graphical Abstract
Scheme 1: Cobalt-catalyzed C–H carbonylation.
Scheme 2: Hydroarylation by C–H activation.
Scheme 3: Pathways for cobalt-catalyzed hydroarylations.
Scheme 4: Co-catalyzed hydroarylation of alkynes with azobenzenes.
Scheme 5: Co-catalyzed hydroarylation of alkynes with 2-arylpyridines.
Scheme 6: Co-catalyzed addition of azoles to alkynes.
Scheme 7: Co-catalyzed addition of indoles to alkynes.
Scheme 8: Co-catalyzed hydroarylation of alkynes with imines.
Scheme 9: A plausible pathway for Co-catalyzed hydroarylation of alkynes.
Scheme 10: Co-catalyzed anti-selective C–H addition to alkynes.
Scheme 11: Co(III)-catalyzed hydroarylation of alkynes with indoles.
Scheme 12: Co(III)-catalyzed branch-selective hydroarylation of alkynes.
Scheme 13: Co(III)-catalyzed hydroarylation of terminal alkynes with arenes.
Scheme 14: Co(III)-catalyzed hydroarylation of alkynes with amides.
Scheme 15: Co(III)-catalyzed C–H alkenylation of arenes.
Scheme 16: Co-catalyzed alkylation of substituted benzamides with alkenes.
Scheme 17: Co-catalyzed switchable hydroarylation of styrenes with 2-aryl pyridines.
Scheme 18: Co-catalyzed linear-selective hydroarylation of alkenes with imines.
Scheme 19: Co-catalyzed linearly-selective hydroarylation of alkenes with N–H imines.
Scheme 20: Co-catalyzed branched-selective hydroarylation of alkenes with imines.
Scheme 21: Mechanism of Co-catalyzed hydroarylation of alkenes.
Scheme 22: Co-catalyzed intramolecular hydroarylation of indoles.
Scheme 23: Co-catalyzed asymmetric hydroarylation of alkenes with indoles.
Scheme 24: Co-catalyzed hydroarylation of alkenes with heteroarenes.
Scheme 25: Co(III)-catalyzed hydroarylation of activated alkenes with 2-phenyl pyridines.
Scheme 26: Co(III)-catalyzed C–H alkylation of arenes.
Scheme 27: Co(III)-catalyzed C2-alkylation of indoles.
Scheme 28: Co(III)-catalyzed switchable hydroarylation of alkyl alkenes with indoles.
Scheme 29: Co(III)-catalyzed C2-allylation of indoles.
Scheme 30: Co(III)-catalyzed ortho C–H alkylation of arenes with maleimides.
Scheme 31: Co(III)-catalyzed hydroarylation of maleimides with arenes.
Scheme 32: Co(III)-catalyzed hydroarylation of allenes with arenes.
Scheme 33: Co-catalyzed hydroarylative cyclization of enynes with carbonyl compounds.
Scheme 34: Mechanism for the Co-catalyzed hydroarylative cyclization of enynes with carbonyl compounds.
Scheme 35: Co-catalyzed addition of 2-arylpyridines to aromatic aldimines.
Scheme 36: Co-catalyzed addition of 2-arylpyridines to aziridines.
Scheme 37: Co(III)-catalyzed hydroarylation of imines with arenes.
Scheme 38: Co(III)-catalyzed addition of arenes to ketenimines.
Scheme 39: Co(III)-catalyzed three-component coupling.
Scheme 40: Co(III)-catalyzed hydroarylation of aldehydes.
Scheme 41: Co(III)-catalyzed addition of arenes to isocyanates.
An uracil-linked hydroxyflavone probe for the recognition of ATP
- Márton Bojtár,
- Péter Zoltán Janzsó-Berend,
- Dávid Mester,
- Dóra Hessz,
- Mihály Kállay,
- Miklós Kubinyi and
- István Bitter
Beilstein J. Org. Chem. 2018, 14, 747–755, doi:10.3762/bjoc.14.63
- , 4’-dimethylaminohydroxyflavone) was utilized by Pivovarenko and co-workers in ATP sensing in aqueous solution and in mitochondria [34][44]. DMHF was found to form 1:1 and 1:2 complexes with ATP. The two components were held together by π-stacking and by electrostatic interactions of the positively
Graphical Abstract
Figure 1: Structures of the studied hydroxyflavone derivatives.
Figure 2: Optimized geometries for (a) DEHF∙ATP, (b) UHF∙ATP with the adenine of ATP “sandwiched” between the...
Scheme 1: Synthesis of UHF. (i) 4-Dimethylaminobenzaldehyde, DMF, NaOMe, rt, 17 h, (ii) hydrogen peroxide, Na...
Figure 3: Variation of fluorescence spectra of UHF (1.0 μM) upon addition of increasing amounts of ATP in 0.0...
Figure 4: Excitation spectra of UHF (dark green line, 1 μM) and UHF + 300 equiv ATP (red line), measured at d...
Figure 5: Fluorescence enhancement (F/F0) values of UHF (1.0 μM) upon addition of different nucleotides at 54...
Figure 6: Ratio of the fluorescence intensities at 540 nm, the samples were excited at 470 and 400 nm. The re...
Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing
- Françoise Debart,
- Christelle Dupouy and
- Jean-Jacques Vasseur
Beilstein J. Org. Chem. 2018, 14, 436–469, doi:10.3762/bjoc.14.32
- PNATAR fragment directed against the TAR RNA region of the HIV genome conjugated to TPP inhibited HIV replication in CEM cell lines with an IC50 of 1 μM, while the unconjugated 16-mer PNATAR was inactive in these tests. The anti-HIV activity confirmed that the PNATAR was not sequestered in mitochondria
Graphical Abstract
Scheme 1: Demasking under reducing agents of ON prodrugs modified as phosphotriesters with A) benzyl groups [13] ...
Scheme 2: A) Synthesis via phosphoramidite chemistry and B) demasking under the reducing environment of 2’-O-...
Scheme 3: Synthesis via phosphoramidite chemistry of various 2’-O-alkyldithiomethyl (RSSM)-modified RNAs bear...
Scheme 4: A) siRNA conjugates to cholesterol [19] and B) PNA conjugates to a triphenylphosphonium [20] through a disu...
Scheme 5: Synthesis via phosphoramidite chemistry and deprotection mediated by nitroreductase/NADH of hypoxia...
Scheme 6: Synthesis via phosphoramidite chemistry and conversion mediated by nitroreductase/NADH of hypoxia-a...
Scheme 7: Incorporation of O6-(4-nitrobenzyl)-2’-deoxyguanosine into an ON prone to form a G-quadruplex struc...
Scheme 8: Synthesis and mechanism for the demasking of ON prodrugs from A) S-acylthioethyl phosphotriester [29] a...
Figure 1: Oligothymidylates bearing A) 2,2-bis(ethoxycarbonyl)-3-(pivaloyloxy)propyl- and B) 2-cyano-2(2-phen...
Figure 2: Oligothymidylates containing esterase and thermo-labile (4-acetylthio-2,2-dimethyl-3-oxobutyl) phos...
Scheme 9: Phosphoramidites and the corresponding RNA prodrugs protected as A) t-Bu-SATE, B) OH-SATE and C) A-...
Scheme 10: Mechanism of the hydrolysis of 2’-O-acyloxymethyl ONs mediated by carboxyesterases [46]. The hydrolysis...
Scheme 11: Synthesis of partially 2’-O-PivOM-modified RNAs [49] and 2’-O-PiBuOM-modified RNAs [53] using their corresp...
Figure 3: A) 2’-O-amino and guanidino-containing acetal ester phosphoramidites and B) 2’-O-(amino acid) aceta...
Scheme 12: Prodrugs of tricyclo-ONs functionalized with A) ethyl (tcee-T) and B) hexadecyl (tchd-T) ester func...
Scheme 13: Demasking mechanism of fma thiophosphate triesters in CpG ODN upon heat action [58].
Scheme 14: Thermolytic cleavage of the hydroxy-alkylated thiophosphate and phosphato-/thiophosphato-alkylated ...
Scheme 15: Synthesis via phosphoramidite chemistry and thermolytic cleavage of alkylated (diisopropyl, diethyl...
Scheme 16: Synthesis of thermosensitive prodrugs of ODNs containing fma thiophosphate triesters combined to po...
Scheme 17: Caging of deoxycytidine in methylphosphonate ONs by using the thermolabile phenylsulfonylcarbamoyl ...
Figure 4: Biotinylated 1-(5-(aminomethyl)-2-nitrophenyl)ethyl phosphoramidite used to cage the 5’-end of a si...
Scheme 18: Introduction and cleavage of 1-(4,5-dimethoxy-2-nitrophenyl)ethyl (DMNPE) [74] and cyclododecyl-DMNPE (...
Scheme 19: Post-synthetic introduction of a thioether-enol phosphodiester (TEEP) linkage into a DNAzyme by the...
Scheme 20: A) NPP dT and dG phosphoramidites [91,92] and B) NPOM U and G phosphoramidites [83] used to introduce photocag...
Scheme 21: Introduction of the photocaged 3-NPOM nucleobase into phosphorothioate antisense and morpholino ant...
Scheme 22: Control of the activity of an antisense ODN using a photocaged hairpin [82]. Formation of the hairpin s...
Scheme 23: Control of alternative splicing using phosphorothioate (PS) 2’-OMe-photocaged ONs resulting from th...
Scheme 24: A) Light activation of a photocaged DNAzyme incorporating 3-NPOM thymidine in its catalytic site [87]; ...
Scheme 25: Incorporation of 3-(6-nitropiperonyloxymethyl) (NPOM) thymidine and 4-nitropiperonylethyl (NPE) deo...
Scheme 26: Synthesis of a photocaged DNA decoy from a 3-NPOM thymidine phosphoramidite and release of the NPOM...
Scheme 27: Synthesis of a caged DNA decoy hairpin containing a 7-nitroindole nucleotide and release of the mod...
Figure 5: Caged-2’-adenosines used by MacMillan et al [93,94] (X = O) and Piccirilli et al [95] (X = S) to study RNA mec...
Scheme 28: Synthesis of circular ODNs containing a photolabile linker as described by Tang et al. [101,104].
Scheme 29: Control of RNA digestion with RNase H using light activation of a photocaged hairpin [97].
Scheme 30: Photocontrol of RNA degradation using caged circular antisense ODNs containing a photoresponsive li...
Scheme 31: Control of RNA translation using an “RNA bandage” consisting of two short 2’-OMe ONs linked togethe...
Scheme 32: Control of alternative splicing using photocaged ONs resulting from the incorporation of an o-nitro...
Scheme 33: A) Light deactivation of a photocaged DNAzyme incorporating one photocleavable spacer in its cataly...
Scheme 34: Solid-phase synthesis of a caged vit E-siRNA conjugate and its release upon UV irradiation [106].
Scheme 35: Synthesis of a siRNA conjugated to a nanoparticle (NP) via a cyclooctene heterolinker from a siRNA-...
Vinylphosphonium and 2-aminovinylphosphonium salts – preparation and applications in organic synthesis
- Anna Kuźnik,
- Roman Mazurkiewicz and
- Beata Fryczkowska
Beilstein J. Org. Chem. 2017, 13, 2710–2738, doi:10.3762/bjoc.13.269
- anticancer drugs, antioxidants, or functional probes into the mitochondria [5][6][7][8]. Review 1. Synthesis of vinylphosphonium salts 1.1. Alkylation of phosphines with alkyl halides One of the most common methods for the preparation of vinylphosphonium salts 1 is the quaternization of vinylphosphines with
Graphical Abstract
Scheme 1: Generation of phosphorus ylides from vinylphosphonium salts.
Scheme 2: Intramolecular Wittig reaction with the use of vinylphosphonium salts.
Scheme 3: Alkylation of diphenylvinylphosphine with methyl or benzyl iodide.
Scheme 4: Methylation of isopropenyldiphenylphosphine with methyl iodide.
Scheme 5: Alkylation of phosphines with allyl halide derivatives and subsequent isomerization of intermediate...
Scheme 6: Alkylation of triphenylphosphine with vinyl triflates in the presence of (Ph3P)4Pd.
Scheme 7: Mechanism of alkylation of triphenylphosphine with vinyl triflates in the presence of (Ph3P)4Pd as ...
Scheme 8: β-Elimination of phenol from β-phenoxyethyltriphenylphosphonium bromide.
Scheme 9: β-Elimination of phenol from β-phenoxyethylphosphonium salts in an alkaline environment.
Scheme 10: Synthesis and subsequent dehydrohalogenation of α-bromoethylphosphonium bromide.
Scheme 11: Synthesis of tributylvinylphosphonium iodides via Peterson-type olefination of α-trimethylsilylphos...
Scheme 12: Synthesis of 1-cycloalkenetriphenylphosphonium salts by electrochemical oxidation of triphenylphosp...
Scheme 13: Suggested mechanism for the electrochemical synthesis of 1-cycloalkenetriphenylphosphonium salts.
Scheme 14: Generation of α,β-(dialkoxycarbonyl)vinylphosphonium salts by addition of triphenylphosphine to ace...
Scheme 15: Synthesis of 2-(N-acylamino)vinylphosphonium halides by imidoylation of β-carbonyl ylides with imid...
Scheme 16: Imidoylation of β-carbonyl ylides with imidoyl halides generated in situ.
Scheme 17: Synthesis of 2-benzoyloxyvinylphosphonium bromide from 2-propynyltriphenylphosphonium bromide.
Scheme 18: Synthesis of 2-aminovinylphosphonium salts via nucleophilic addition of amines to 2-propynyltriphen...
Scheme 19: Deacylation of 2-(N-acylamino)vinylphosphonium chlorides to 2-aminovinylphosphonium salts.
Scheme 20: Resonance structures of 2-aminovinylphosphonium salts and tautomeric equilibrium between aminovinyl...
Scheme 21: Synthesis of 2-aminovinylphosphonium salts by reaction of (formylmethyl)triphenylphosphonium chlori...
Scheme 22: Generation of ylides by reaction of vinyltriphenylphosphonium bromide with nucleophiles and their s...
Scheme 23: Intermolecular Wittig reaction with the use of vinylphosphonium bromide and organocopper compounds ...
Scheme 24: Intermolecular Wittig reaction with the use of ylides generated from vinylphosphonium bromides and ...
Scheme 25: Direct transformation of vinylphosphonium salts into ylides in the presence of potassium tert-butox...
Scheme 26: A general method for synthesis of carbo- and heterocyclic systems by the intramolecular Wittig reac...
Scheme 27: Synthesis of 2H-chromene by reaction of vinyltriphenylphosphonium bromide with sodium 2-formylpheno...
Scheme 28: Synthesis of 2,5-dihydro-2,3-dimethylfuran by reaction of vinylphosphonium bromide with 3-hydroxy-2...
Scheme 29: Synthesis of 2H-chromene and 2,5-dihydrofuran derivatives in the intramolecular Wittig reaction wit...
Scheme 30: Enantioselective synthesis of 3,6-dihydropyran derivatives from vinylphosphonium bromide and enanti...
Scheme 31: Synthesis of 2,5-dihydrothiophene derivatives in the intramolecular Wittig reaction from vinylphosp...
Scheme 32: Synthesis of bicyclic pyrrole derivatives in the reaction of vinylphosphonium halides and 2-pyrrolo...
Scheme 33: Stereoselective synthesis of bicyclic 2-pyrrolidinone derivatives in the reaction of vinylphosphoni...
Scheme 34: Stereoselective synthesis of 3-pyrroline derivatives in the intramolecular Wittig reaction from vin...
Scheme 35: Synthesis of cyclic alkenes in the intramolecular Wittig reaction from vinylphosphonium bromide and...
Scheme 36: Synthesis of 1,3-cyclohexadienes by reaction of 1,3-butadienyltriphenylphosphonium bromide with eno...
Scheme 37: Synthesis of bicyclo[3.3.0]octenes by reaction of vinylphosphonium salts with cyclic diketoester.
Scheme 38: Synthesis of quinoline derivatives in the intramolecular Wittig reaction from 2-(2-acylphenylamino)...
Scheme 39: Stereoselective synthesis of γ-aminobutyric acid in the intermolecular Wittig reaction from chiral ...
Scheme 40: Synthesis of allylamines in the intermolecular Wittig reaction from 2-aminovinylphosphonium bromide...
Scheme 41: A general route towards α,β-di(alkoxycarbonyl)vinylphosphonium salts and their subsequent possible ...
Scheme 42: Generation of resonance-stabilized phosphorus ylides via the reaction of triphenylphosphine with di...
Scheme 43: Synthesis of resonance-stabilized phosphorus ylides in the reaction of triphenylphosphine, dialkyl ...
Scheme 44: Synthesis of resonance-stabilized phosphorus ylides via the reaction of triphenylphosphine with dia...
Scheme 45: Generation of resonance-stabilized phosphorus ylides in the reaction of acetylenedicarboxylate, tri...
Scheme 46: Synthesis of resonance-stabilized phosphorus ylides via the reaction of dialkyl acetylenedicarboxyl...
Scheme 47: Synthesis of resonance-stabilized ylides derived from semicarbazones, aromatic amides, and 3-(aryls...
Scheme 48: Synthesis of resonance-stabilized ylides via the reaction of triphenylphosphine with dialkyl acetyl...
Scheme 49: Synthesis of resonance-stabilized ylides in the reaction of triphenylphosphine, dialkyl acetylenedi...
Scheme 50: Synthesis of N-acylated α,β-unsaturated γ-lactams via resonance-stabilized phosphorus ylides derive...
Scheme 51: Synthesis of resonance-stabilized phosphorus ylides derived from 6-amino-N,N'-dimethyluracil and th...
Scheme 52: Generation of resonance-stabilized phosphorus ylides in the reaction of triphenylphosphine, dialkyl...
Scheme 53: Synthesis of resonance-stabilized phosphorus ylides via the reaction of triphenylphosphine with dia...
Scheme 54: Synthesis of 1,3-dienes via intramolecular Wittig reaction with the use of resonance-stabilized yli...
Scheme 55: Synthesis of 1,3-dienes in the intramolecular Wittig reaction from ylides generated from dimethyl a...
Scheme 56: Synthesis of 4-(2-quinolyl)cyclobutene-1,2,3-tricarboxylic acid triesters and isomeric cyclopenteno...
Scheme 57: Synthesis of 4-arylquinolines via resonance-stabilized ylides in the intramolecular Wittig reaction....
Scheme 58: Synthesis of furan derivatives via resonance-stabilized ylides in the intramolecular Wittig reactio...
Scheme 59: Synthesis of 1,3-indanedione derivatives via resonance-stabilized ylides in the intermolecular Witt...
Scheme 60: Synthesis of coumarin derivatives via nucleophilic displacement of the triphenylphosphonium group i...
Scheme 61: Synthesis of 6-formylcoumarin derivatives and their application in the synthesis of dyads.
Scheme 62: Synthesis of di- and tricyclic coumarin derivatives in the reaction of pyrocatechol with two vinylp...
Scheme 63: Synthesis of mono-, di-, and tricyclic derivatives in the reaction of pyrogallol with one or two vi...
Scheme 64: Synthesis of 1,4-benzoxazine derivative by nucleophilic displacement of the triphenylphosphonium gr...
Scheme 65: Synthesis of 7-oxo-7H-pyrido[1,2,3-cd]perimidine derivative via nucleophilic displacement of the tr...
Scheme 66: Application of vinylphosphonium salts in the Diels–Alder reaction with dienes.
Scheme 67: Synthesis of pyrroline derivatives from vinylphosphonium bromide and 5-(4H)-oxazolones.
Scheme 68: Synthesis of pyrrole derivatives in the reactions of vinyltriphenylphosphonium bromide with protona...
Scheme 69: Synthesis of dialkyl 2-(alkylamino)-5-aryl-3,4-furanedicarboxylates via intermediate α,β-di(alkoxyc...
Scheme 70: Synthesis of 1,4-benzoxazine derivatives from acetylenedicarboxylates, phosphines, and 1-nitroso-2-...
Pyrene–nucleobase conjugates: synthesis, oligonucleotide binding and confocal bioimaging studies
- Artur Jabłoński,
- Yannic Fritz,
- Hans-Achim Wagenknecht,
- Rafał Czerwieniec,
- Tytus Bernaś,
- Damian Trzybiński,
- Krzysztof Woźniak and
- Konrad Kowalski
Beilstein J. Org. Chem. 2017, 13, 2521–2534, doi:10.3762/bjoc.13.249
- . Confocal microscopy confirmed that 5 predominantly stains mitochondria but it also accumulates in the nucleoli of the cells. Keywords: confocal microscopy; luminescence; nucleobases; oligonucleotide binding; pyrene; X-ray; Introduction Pyrene is a planar, polycyclic aromatic hydrocarbon which shows well
- ) and 0.71 ± 0.11 (for 5). Likewise, the average values of PCC were 0.67 ± 0.09 (for 4) and 0.55 ± 0.06 (for 5). These data are compatible with preferential, but not exclusive localization of both compounds in mitochondria. This effect is slightly more pronounced (at p = 0.05) for 4, as compared with 5
- -like binding, intercalation, or a mixture of both. Confocal microscopy revealed a similar cellular staining pattern for compounds 4 and 5. Both derivatives predominantly accumulate in mitochondria of living HeLa cells and the adenine conjugate 5 accumulates also in the nucleoli of the cells. Our
Graphical Abstract
Figure 1: Examples of pyrene derivatives with relevance to nucleic acid chemistry and structures of pyrenyl–n...
Scheme 1: Synthesis of pyrene–nucleobase conjugates 2–5.
Figure 2: ORTEP diagram of 2 at 50% probability level. The hydrogen and halogen bonds are represented by dash...
Figure 3: Intermolecular hydrogen bonding (N22–H22···O27 distance = 2.882(2) Å) and halogen bonding (C30–Cl31...
Figure 4: UV–vis absorption and fluorescence spectra of pyrene–adenines 5 (a) and 3 (b) in diluted (c ≈ 10−5 ...
Figure 5: Absorption changes during titration of 2 and 4 (λ = 344 nm) in the presence of (dA)10, and 3 and 5 ...
Figure 6: Cellular distribution of 4 in living HeLa cells. (A) Fluorescence of 4 (green). (B) Fluorescence of...
Figure 7: Cellular distribution of 5 in living HeLa cells. (A) Fluorescence of 5 (green). Arrows are marking ...
18-Hydroxydolabella-3,7-diene synthase – a diterpene synthase from Chitinophaga pinensis
- Jeroen S. Dickschat,
- Jan Rinkel,
- Patrick Rabe,
- Arman Beyraghdar Kashkooli and
- Harro J. Bouwmeester
Beilstein J. Org. Chem. 2017, 13, 1770–1780, doi:10.3762/bjoc.13.171
- test the catalytic activity of HdS in planta, its corresponding gene was transiently expressed in N. benthamiana. Since we have shown before that the mitochondria are a suitable subcellular compartment for the heterologous production of terpenes [26], and it is known that one of the multiple GGPP
- synthases in plants are targeted to the mitochondria [27], we decided to attempt the expression of HdS with mitochondrial targeting (HdS-mit). A construct without targeting signal (HdS; resulting in cytoplasmic localisation) and an empty vector were used as controls. A p19 construct [28] was co-infiltrated
- targeting to the mitochondria resulted in the production of the same diterpene alcohol. Although the mitochondria of N. benthamiana also produce FPP [32], again no germacrene D was detected. Taken together, these experiments demonstrate that the expression of one and the same terpene synthase in different
Graphical Abstract
Scheme 1: Germacrene A (1) and its Cope rearrangement to β-elemene (2).
Figure 1: In vitro terpene synthase activity of the investigated recombinant enzyme from C. pinensis, showing...
Scheme 2: Product obtained from the diterpene synthase from C. pinensis. (A) Structure of (1R,3E,7E,11S,12S)-...
Figure 2: Determination of the absolute configuration of 3. (A) Partial HSQC spectrum of unlabelled 3 showing...
Figure 3: Determination of the absolute configuration of 3. (A) Partial HSQC spectrum of unlabelled 3 showing...
Figure 4: Assignment of H6α and H6β of 3. (A) Partial HSQC spectrum of unlabelled 3 showing the region for C6...
Figure 5: Partial 13C NMR spectra of A) unlabeled 3, B) (13C1)-3 arising from incubation of HdS and GGPPS wit...
Figure 6: Transient expression of 18-hydroxydolabella-3,7-diene synthase (HdS) in Nicotiana benthamiana. Tota...
The chemistry and biology of mycolactones
- Matthias Gehringer and
- Karl-Heinz Altmann
Beilstein J. Org. Chem. 2017, 13, 1596–1660, doi:10.3762/bjoc.13.159
- significant binding to the nucleus, mitochondria or actin being detectable. Similar results were obtained by Blanchard and co-workers with the fully synthetic 8-desmethylmycolactone analog 13, which bears a BODIPY tag as a partial replacement for the core extension [92]. According to unpublished data from the
Graphical Abstract
Figure 1: Initial proposal for the core macrolactone structure (left) and the established complete structure ...
Figure 2: Mycolactone congeners and their origins.
Figure 3: Misassigned mycolactone E structure according to Small et al. [50] (11) and the correct structure (6) f...
Figure 4: Schematic illustration of Kishi’s improved mycolactone TLC detection method exploiting derivatizati...
Figure 5: Fluorescent probes derived from natural mycolactone A/B (1a,b) or its synthetic 8-desmethyl analogs...
Figure 6: Tool compounds used by Pluschke and co-workers for elucidating the molecular targets of mycolactone...
Figure 7: Synthetic strategies towards the extended mycolactone core. A) General strategies. B) Kishi’s appro...
Scheme 1: Kishi’s 1st generation approach towards the extended core structure of mycolactones. Reagents and c...
Scheme 2: Kishi’s 2nd generation approach towards the extended core structure of mycolactones. Reagents and c...
Scheme 3: Kishi’s 3rd generation approach towards the extended core structure of mycolactones. Reagents and c...
Scheme 4: Negishi’s synthesis of the extended core structure of mycolactones. Reagents and conditions: a) (i) ...
Scheme 5: Burkart’s (incomplete) 1st generation approach towards the extended core structure of mycolactones....
Scheme 6: Burkart’s (incomplete) 1st, 2nd and 3rd generation approach towards the extended mycolactone core s...
Scheme 7: Altmann’s synthesis of alkyl iodide 91. Reagents and conditions: a) (i) PMB-trichloroacetimidate, T...
Scheme 8: Final steps of Altmann’s synthesis of the extended core structure of mycolactones. Reagents and con...
Scheme 9: Basic principles of the Aggarwal lithiation–borylation homologation process [185,186].
Scheme 10: Aggarwal’s synthesis of the C1–C11 fragment of the mycolactone core. Reagents and conditions: a) Cl...
Scheme 11: Aggarwal’s synthesis of the linear C1–C20 fragment of the mycolactone core. Reagents and conditions...
Figure 8: Synthetic strategies towards the mycolactone A/B lower side chain.
Scheme 12: Gurjar and Cherian’s synthesis of the C1’–C8’ fragment of the mycolactone A/B pentaenoate side chai...
Scheme 13: Gurjar and Cherian’s synthesis of the benzyl-protected mycolactone A/B pentaenoate side chain. Reag...
Scheme 14: Kishi’s synthesis of model compounds for elucidating the stereochemistry of the C7’–C16’ fragment o...
Scheme 15: Kishi’s synthesis of the mycolactone A/B pentaenoate side chain. (a) (i) NaH, (EtO)2P(O)CH2CO2Et, T...
Scheme 16: Feringa and Minnaard's incomplete synthesis of mycolactone A/B pentaenoate side chain. Reagents and...
Scheme 17: Altmann’s approach towards the mycolactone A/B pentaenoate side chain. Reagents and conditions: a) ...
Scheme 18: Negishi’s access to the C1’–C7’ fragment of mycolactone A. Reagents and conditions: a) (i) n-BuLi, ...
Scheme 19: Negishi’s approach to the C1’–C7’ fragment of mycolactone B. Reagents and conditions: a) (i) DIBAL-...
Scheme 20: Negishi’s synthesis of the C8’–C16’ fragment of mycolactone A/B. Reagents and conditions: a) 142, BF...
Scheme 21: Negishi’s assembly of the mycolactone A and B pentaenoate side chains. Reagents and conditions: a) ...
Scheme 22: Blanchard’s approach to the mycolactone A/B pentaenoate side chain. a) (i) Ph3P=C(Me)COOEt, CH2Cl2,...
Scheme 23: Kishi’s approach to the mycolactone C pentaenoate side chain exemplified for the 13’R,15’S-isomer 1...
Scheme 24: Altmann’s (unpublished) synthesis of the mycolactone C pentaenoate side chain. Reagents and conditi...
Scheme 25: Blanchard’s synthesis of the mycolactone C pentaenoate side chain. Reagents and conditions: a) (i) ...
Scheme 26: Kishi’s synthesis of the tetraenoate side chain of mycolactone F exemplified by enantiomer 165. Rea...
Scheme 27: Kishi’s synthesis of the mycolactone E tetraenoate side chain. Reagents and conditions: a) (i) CH2=...
Scheme 28: Wang and Dai’s synthesis of the mycolactone E tetraenoate side chain. Reagents and conditions: a) (...
Scheme 29: Kishi’s synthesis of the dithiane-protected tetraenoate side chain of the minor oxo-metabolite of m...
Scheme 30: Kishi’s synthesis of the mycolactone S1 and S2 pentaenoate side chains. Reagents and conditions: a)...
Scheme 31: Kishi’s 1st generation and Altmann’s total synthesis of mycolactone A/B (1a,b) and Negishi’s select...
Scheme 32: Kishi’s 2nd generation total synthesis of mycolactone A/B (1a,b). Reagents and conditions: a) 2,4,6...
Scheme 33: Blanchard’s synthesis of the 8-desmethylmycolactone core. Reagents and conditions: a) (i) TsCl, TEA...
Scheme 34: Altmann’s (partially unpublished) synthesis of the C20-hydroxylated mycolactone core. Reagents and ...
Scheme 35: Altmann’s and Blanchard’s approaches towards the 11-isopropyl-8-desmethylmycolactone core. Reagents...
Scheme 36: Blanchard’s synthesis of the saturated variant of the C11-isopropyl-8-desmethylmycolactone core. Re...
Scheme 37: Structure elucidation of photo-mycolactones generated from tetraenoate 224.
Scheme 38: Kishi’s synthesis of the linear precursor of the photo-mycolactone B1 lower side chain. Reagents an...
Scheme 39: Kishi’s synthesis of the photo-mycolactone B1 lower side chain. Reagents and conditions: a) LiTMP, ...
Scheme 40: Kishi’s synthesis of a stabilized lower mycolactone side chain. Reagents and conditions: a) (i) TBD...
Scheme 41: Blanchard’s variation of the C12’,C13’,C15’ stereocluster. Reagents and conditions: a) (i) DIBAL-H,...
Scheme 42: Blanchard’s synthesis of aromatic mycolactone polyenoate side chain analogs. Reagents and condition...
Scheme 43: Small’s partial synthesis of a BODIPY-labeled mycolactone derivative and Demangel’s partial synthes...
Scheme 44: Blanchard’s synthesis of the BODIPY-labeled 8-desmethylmycolactones. Reagents and conditions: a) (i...
Scheme 45: Altmann’s synthesis of biotinylated mycolactones. Reagents and conditions: a) (i) CDI, THF, rt, 2 d...
Figure 9: Kishi’s elongated n-butyl carbamoyl mycolactone A/B analog.
From chemical metabolism to life: the origin of the genetic coding process
- Antoine Danchin
Beilstein J. Org. Chem. 2017, 13, 1119–1135, doi:10.3762/bjoc.13.111
Graphical Abstract
Figure 1: Selective surface metabolism. Prebiotic carbon-based molecules accumulated in a neutral or slightly...
Figure 2: Building up membranes, peptides and co-enzymes. Thioester-based metabolism resulted in the synthesi...
Figure 3: The RNA metabolism world. Among molecules built up by a swinging-arm thioester are pyrimidines coup...
Opportunities and challenges for the sustainable production of structurally complex diterpenoids in recombinant microbial systems
- Katarina Kemper,
- Max Hirte,
- Markus Reinbold,
- Monika Fuchs and
- Thomas Brück
Beilstein J. Org. Chem. 2017, 13, 845–854, doi:10.3762/bjoc.13.85
- the diverse biosynthesis of the structurally highly diverse family of isoprenoids. Both pathways use intermediate products of the central sugar metabolism as carbon sources [25]. In most eukaryotes (all mammals, yeast, fungi, archaea and plants (more precisely in the cytosol and mitochondria)) the
Graphical Abstract
Scheme 1: Isoprenoid biosynthetic pathways and examples for their engineering in heterologous production syst...
Scheme 2: Mutational engineering of different classes of terpene synthases. Left side: The natural product of...
Figure 1: Implementation of a microbial cell factory. 1: Selection of enzymes from different species. P450 an...
Derivatives of the triaminoguanidinium ion, 5. Acylation of triaminoguanidines leading to symmetrical tris(acylamino)guanidines and mesoionic 1,2,4-triazolium-3-aminides
- Jan Szabo,
- Julian Greiner and
- Gerhard Maas
Beilstein J. Org. Chem. 2017, 13, 579–588, doi:10.3762/bjoc.13.57
- biological activities have been reported for some of the other types of mesoionic heterocycles. For example, antitumor [27][28][29], antileishmanial [30] and trypanocidal [31] activities, as well as reduction of the phosphorylation efficiency of rat liver mitochondria [32], have been described for 1,3,4
Graphical Abstract
Scheme 1: Reactions of aminoguanidines with carboxylic acids and acid chlorides. The structural formulae show...
Scheme 2: Threefold N-acylation of triaminoguanidinium chloride (1) with acyl chloride 2b.
Scheme 3: Reaction of 1,2,3-tris(benzylamino)guanidinium salts 4 and 5 with acyl chlorides to give 1,2,3-tris...
Figure 1: Molecular structure of 6b·2C2H5OH in the solid state, with numbering of atoms (ORTEP plot). Selecte...
Scheme 4: Protonation and methylation of 1,2,4-triazolium-3-aminides 7b,c.
Scheme 5: Catalytic hydrogenation/debenzylation of betaines 7.
Figure 2: Left: molecular structure of 8b in the solid state (OLEX2 plot). Right: crystal structure viewed al...
Figure 3: Left: solid-state structure of 9b·H2O (ORTEP plot). Right: centrosymmetric hydrogen-bonded dimer of...
Figure 4: Solid-state structure of mesoionic compound 7a (ORTEP plot); thermal displacement ellipsoids are dr...
Figure 5: UV–vis spectra of 7a–d in chloroform (c = 0.04 mmol L−1); λmax [nm] (ε [L mol−1 cm−1]): 7a: 350 (47...
Synthesis of spiro[isoindole-1,5’-isoxazolidin]-3(2H)-ones as potential inhibitors of the MDM2-p53 interaction
- Salvatore V. Giofrè,
- Santa Cirmi,
- Raffaella Mancuso,
- Francesco Nicolò,
- Giuseppe Lanza,
- Laura Legnani,
- Agata Campisi,
- Maria A. Chiacchio,
- Michele Navarra,
- Bartolo Gabriele and
- Roberto Romeo
Beilstein J. Org. Chem. 2016, 12, 2793–2807, doi:10.3762/bjoc.12.278
- the damage is repaired. If the damage is too severe, p53 trigs apoptosis which allows the elimination of damaged cells, also by its translocation in the mitochondria where it inhibits the activity of anti-apoptotic proteins. Many tumors overproduce MDM2 to impair p53 function, thus promoting
Graphical Abstract
Figure 1: Some relevant MDM2-p53 interaction inhibitors.
Figure 2: Retrosynthetic route to spiro[isoindole-1,5-isoxazolidin]-3(2H)-ones 3.
Scheme 1: Synthesis of compounds 2.
Scheme 2: Synthesis of 6a–f by 1,3-dipolar cycloaddition.
Figure 3: Selected NOESY observed for compounds 6a and 7a.
Figure 4: ORTEP drawing of the X-ray crystal structure of 7a showing the model atomic numbering scheme (C10 a...
Scheme 3: Reaction pathway.
Figure 5: Three-dimensional plots of TSs of reaction of dipolarophiles (Z)-8 and (E)-8 with nitrone 4. The la...
Figure 6: Free energy profiles for the cycloaddition reaction of the two isomers Z (A) or E (B) of dipolaroph...
Figure 7: Compound 6e reduces cancer cell proliferation. Treatment of SH-SY5Y, HT-29 and HepG2 cells with 6e ...
Figure 8: Cytotoxic effect of 6e. The cytotoxic activity of 6e was assessed in terms of both LDH release (a) ...
Figure 9: 6e modulate the levels of p53 in SH-SY5Y cells. (a) The SH-SY5Y cells were treated for 24 h with th...
Figure 10: (A) Representative Western Blots and (B) semiquantitative analyses of p53, MDM2, p21 expression lev...
Figure 11: (A) Representative Western Blots and (B) densitometric analysis of caspase-3 and PARP cleavage in t...
Figure 12: Compounds 6a (green) and 6c (blue) docked into MDM2 structure (PDB-ID: 3LBL) superimposed on the ke...
Figure 13: A) Compounds 6e (green) docked into MDM2 structure (PDB-ID: 3LBL); His96 and p53 residue (yellow st...
Antibiotics from predatory bacteria
- Juliane Korp,
- María S. Vela Gurovic and
- Markus Nett
Beilstein J. Org. Chem. 2016, 12, 594–607, doi:10.3762/bjoc.12.58
- respiratory chain. They were shown to block the electron flow at complex I of mitochondria (NADH:ubiquinone oxidoreductase) in a competitive manner, but do not act on bacterial complex I [71][72]. This explains why the myxalamids are mainly active against fungi [71]. The myxovirescins comprise a family of
Graphical Abstract
Figure 1: Natural products isolated from M. xanthus DK1622. DKxanthene-534 (1); myxalamid B (2); myxovirescin...
Figure 2: Vegetative cells of P. fallax HKI 727 under a phase-contrast microscope (K. Martin, unpublished). B...
Figure 3: Structures of myxopyronins A (11) and B (12), corallopyronins A (13), B (14) and C (15), as well as...
Figure 4: Structure of althiomycin (17).
Figure 5: Structures of cystobactamids 919-1 (18), 919-2 (19), and 507 (20).
Figure 6: Structures of natural products isolated from Herpetosiphon spp.: siphonazole (21); auriculamide (22...
